
    
      This is a 12-week blinded cross over trial of metformin in PH-HFpEF to improve exercise
      hemodynamics, functional capacity, and glucose metabolism. This phase II clinical trial will
      provide detailed phenotyping, physiological and mechanistic data on PH-HFpEF.
    
  